New Federal Contractors — August 01, 2026

Regeneron secured a 10-year, cost-plus-fixed-fee contract from HHS/BARDA, minimizing profit volatility and ensuring cost recovery. The full-and-open competition signals a competitive win in pandemic preparedness, with $238.8M already outlaid.

AT&T's firm-fixed-price delivery order ended in March 2021 with only $27.3M outlaid, indicating partial execution. This mature award offers no forward-looking investment insight.

Two Lockheed Martin NASA contracts (totaling $18.8M) ended in 2020 and 2023, with no options exercised. Combined, they represent less than 0.03% of Lockheed's annual revenue, offering no current or future revenue signal.

Regeneron's $695.7M BARDA contract has a vague description ('IGF::OT::IGF') and a 10-year performance period, creating uncertainty around specific deliverables and execution milestones.

71% of total obligation value ($695.7M of $975.6M) is concentrated in a single Regeneron contract, making the digest's investment story highly dependent on that award's execution.

Lockheed Martin's $17.3M NASA contract was a non-competitive award, suggesting sole-source incumbency. If recompeted, it could face competitive pressure or loss of position.

Regeneron's competitive win at BARDA signals growing government investment in biodefense and pandemic preparedness, potentially opening follow-on contracts for Regeneron or peers in biotechnology R&D.

The Department of State's $261.1M telecommunications contract (now completed) indicates sustained investment in diplomatic infrastructure. AT&T's win suggests potential for follow-on awards for modernized systems.

Regeneron's $695.7M BARDA contract underscores sustained federal commitment to pandemic preparedness and biodefense, with cost-plus pricing reducing contractor risk.

Three of four contracts (AT&T, Lockheed Martin x2) are completed awards with no current revenue, diluting the digest's forward-looking signal. Investors should focus on active contracts for actionable insights.

{"entity" => "Regeneron Pharmaceuticals", "reason" => "The $695.7M BARDA contract is the highest-conviction signal, but execution risk and lack of program visibility warrant close monitoring.", "trigger" => "Future outlay announcements; modifications to the contract; Regeneron's quarterly R&D pipeline updates"}

{"entity" => "AT&T", "reason" => "The $261.1M State Department contract is completed, but any follow-on award for diplomatic telecommunications would be a positive catalyst.", "trigger" => "State Department solicitation for telephone systems at foreign posts"}

{"entity" => "Lockheed Martin", "reason" => "Two small, historical NASA contracts offer no current signal, but re-competitions could indicate competitive dynamics.", "trigger" => "NASA Ames Research Center re-compete for advanced technology R&D (PISCES or similar)"}